|
|
|
|
|
|
Sponsored by: |
Novartis |
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00438360 |
The study will evaluate the efficacy of cyclosporine when administered twice a week compared to continuous administration, in patients with chronic plaque psoriasis.
Condition | Intervention | Phase |
Chronic Plaque Psoriasis |
Drug: Cyclosporine A microemulsion |
Phase III |
MedlinePlus related topics: | Psoriasis |
ChemIDplus related topics: | Cyclosporine Cyclosporin |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A 24-Week, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study, to Evaluate the Effectiveness of Cyclosporine 2,5 mg/kg/Day Bid Twice a Week on Reducing Relapse Rate, in Maintenance Patients With Chronic Plaque Psoriasis |
Estimated Enrollment: | 264 |
Study Start Date: | May 2006 |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Inclusion criteria:
Exclusion criteria:
Responsible Party: | Novartis ( Novartis ) |
Study ID Numbers: | COLO400CIT04 |
First Received: | February 21, 2007 |
Last Updated: | August 13, 2008 |
ClinicalTrials.gov Identifier: | NCT00438360 |
Health Authority: | Italy: The Italian Medicines Agency |
|
|
|
|
|